HomeDiscoveryPipelineEncorafenib (BRAFTOVI™)

Encorafenib (BRAFTOVI™)

Encorafenib (BRAFTOVI™) is a small molecule inhibitor of the BRAF kinase, a key enzyme in the tyrosine kinase/MAPK signaling pathway (TK-RAS-RAF-MEK-ERK), which is often mutated and activated in different tumors, such as melanoma, colorectal cancer, non-small cell lung cancer and others. BRAFTOVI is approved in combination with the MEK inhibitor binimetinib (MEKTOVI) for the treatment of unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation. Based on the promising activity observed in the BEACON Phase III trial for encorafenib in combination with the EGFR tyrosine kinase inhibitor cetuximab with or without binimetinib, these encorafenib combinations are registered (US) or in preregistration (Eu) for the indication of B-RAF mutant colorectal cancer.